ICD-10: C83.93

ICD-10 code C83.93 refers to Non-follicular (diffuse) lymphoma, unspecified, affecting intra-abdominal lymph nodes. This classification falls under the broader category of non-Hodgkin lymphoma (NHL), which encompasses a diverse group of blood cancers that originate in the lymphatic system. Below is a detailed clinical description and relevant information regarding this specific diagnosis.

Clinical Description

Definition

Non-follicular lymphoma, particularly the diffuse type, is characterized by the rapid proliferation of malignant lymphocytes that do not form follicular structures. This type of lymphoma is often aggressive and can present with various symptoms depending on the extent of the disease and the specific lymphatic regions involved.

Characteristics

• Histological Features: Non-follicular lymphomas, including diffuse large B-cell lymphoma (DLBCL), are typically marked by a diffuse pattern of growth. This means that the cancer cells infiltrate the lymph nodes and surrounding tissues without forming distinct nodular structures.
• Subtypes: While C83.93 is classified as "unspecified," it may include various subtypes of diffuse lymphoma, such as DLBCL, which is the most common form of non-Hodgkin lymphoma in adults.

Symptoms

Patients with intra-abdominal lymph node involvement may experience:
- Abdominal pain or discomfort
- Swelling or a palpable mass in the abdomen
- Unexplained weight loss
- Fever and night sweats
- Fatigue

Diagnosis

Diagnosis typically involves:
- Imaging Studies: CT scans or MRI to visualize lymph node enlargement and assess the extent of the disease.
- Biopsy: A definitive diagnosis is made through a biopsy of the affected lymph nodes, which allows for histological examination and classification of the lymphoma.
- Laboratory Tests: Blood tests may be conducted to evaluate overall health and organ function.

Treatment Options

Standard Treatments

Treatment for non-follicular lymphoma, particularly when it involves intra-abdominal lymph nodes, may include:
- Chemotherapy: Often the first line of treatment, using a combination of drugs to target rapidly dividing cancer cells.
- Radiation Therapy: May be used in conjunction with chemotherapy, especially if localized disease is present.
- Targeted Therapy: Newer treatments that specifically target cancer cell characteristics, such as monoclonal antibodies.

Prognosis

The prognosis for patients with C83.93 can vary widely based on several factors, including:
- The specific subtype of lymphoma
- The stage at diagnosis
- Patient age and overall health
- Response to initial treatment

Conclusion

ICD-10 code C83.93 identifies a specific type of non-follicular lymphoma that affects intra-abdominal lymph nodes. Understanding the clinical characteristics, symptoms, diagnostic methods, and treatment options is crucial for effective management of this condition. As with all cancers, early detection and tailored treatment plans significantly improve patient outcomes. For further information or specific case management, consultation with a hematologist or oncologist is recommended.

Non-follicular (diffuse) lymphoma, classified under ICD-10 code C83.93, is a type of non-Hodgkin lymphoma characterized by the diffuse infiltration of malignant lymphoid cells. This condition primarily affects the intra-abdominal lymph nodes, and its clinical presentation can vary significantly among patients. Below is a detailed overview of the clinical presentation, signs, symptoms, and patient characteristics associated with this diagnosis.

Clinical Presentation

General Overview

Non-follicular lymphoma encompasses a range of aggressive lymphomas that do not exhibit the follicular growth pattern typical of some other lymphomas. The diffuse nature of this lymphoma means that it spreads throughout the lymphatic tissue rather than forming discrete masses. This can lead to a variety of clinical manifestations depending on the extent of the disease and the specific lymph nodes involved.

Signs and Symptoms

1. Lymphadenopathy:
   - Patients often present with enlarged lymph nodes, particularly in the abdomen. This can lead to palpable masses in the abdominal region, which may be detected during physical examination or imaging studies[1].

2. Abdominal Pain or Discomfort:
   - Due to the enlargement of intra-abdominal lymph nodes, patients may experience pain or discomfort in the abdominal area. This can be a result of pressure on surrounding organs or tissues[1].

3. B Symptoms:
   - Many patients exhibit "B symptoms," which include:

   • Fever: Unexplained fevers that may be intermittent.
   • Night Sweats: Profuse sweating during the night, often soaking bedclothes.
   • Weight Loss: Significant and unintentional weight loss over a short period[1][2].

4. Gastrointestinal Symptoms:
   - Depending on the involvement of lymph nodes near the gastrointestinal tract, patients may experience symptoms such as nausea, vomiting, or changes in bowel habits, including diarrhea or constipation[2].

5. Fatigue:
   - A common symptom in many cancer patients, fatigue can be profound and debilitating, affecting the patient's quality of life[2].

6. Splenomegaly and Hepatomegaly:
   - In some cases, the disease may lead to enlargement of the spleen (splenomegaly) or liver (hepatomegaly), which can be detected during physical examination or imaging studies[1].

Patient Characteristics

1. Age:
   - Non-follicular lymphomas can occur at any age but are more commonly diagnosed in adults, particularly those over the age of 60[2].

2. Gender:
   - There is a slight male predominance in the incidence of non-Hodgkin lymphomas, including non-follicular types[2].

3. Comorbidities:
   - Patients may have underlying health conditions that can complicate the diagnosis and treatment, such as autoimmune diseases or previous malignancies[2].

4. Immunocompromised Status:
   - Individuals with weakened immune systems, such as those with HIV/AIDS or those undergoing immunosuppressive therapy, are at a higher risk for developing lymphomas, including non-follicular types[2].

5. Family History:
   - A family history of lymphoproliferative disorders may increase the risk of developing non-follicular lymphoma, suggesting a potential genetic predisposition[2].

Conclusion

The clinical presentation of non-follicular (diffuse) lymphoma, particularly in the context of intra-abdominal lymph nodes, is characterized by a range of symptoms including lymphadenopathy, abdominal pain, and systemic "B symptoms." Patient characteristics such as age, gender, and underlying health conditions play a significant role in the disease's manifestation and progression. Early recognition and diagnosis are crucial for effective management and treatment of this aggressive lymphoma type. For further evaluation and management, healthcare providers typically rely on imaging studies, biopsy, and comprehensive clinical assessments to confirm the diagnosis and determine the appropriate therapeutic approach.

ICD-10 code C83.93 refers to "Non-follicular (diffuse) lymphoma, unspecified, intra-abdominal lymph nodes." This classification falls under the broader category of non-Hodgkin lymphoma (NHL), which encompasses various types of lymphomas that do not originate from the follicle center of lymphoid tissue. Below are alternative names and related terms associated with this specific diagnosis.

Alternative Names

1. Diffuse Large B-Cell Lymphoma (DLBCL): While C83.93 is unspecified, it often includes cases of DLBCL, which is the most common subtype of non-follicular lymphoma.
2. Non-Hodgkin Lymphoma, Diffuse Type: This term emphasizes the diffuse nature of the lymphoma, distinguishing it from follicular types.
3. Aggressive Non-Hodgkin Lymphoma: This term may be used to describe the aggressive behavior of diffuse lymphomas, including those affecting intra-abdominal lymph nodes.

Related Terms

1. Lymphadenopathy: This term refers to the enlargement of lymph nodes, which is a common symptom in lymphomas, including C83.93.
2. Lymphoma: A general term for cancers that originate in the lymphatic system, which includes both Hodgkin and non-Hodgkin lymphomas.
3. Stage IV Lymphoma: If the lymphoma has spread to the intra-abdominal lymph nodes, it may be classified as stage IV, indicating advanced disease.
4. B-cell Lymphoma: Since many non-follicular lymphomas are of B-cell origin, this term is often used in clinical discussions.
5. Extranodal Lymphoma: This term may apply if the lymphoma affects organs outside of the lymph nodes, which can include intra-abdominal sites.

Clinical Context

Understanding these alternative names and related terms is crucial for healthcare professionals involved in the diagnosis and treatment of lymphomas. Accurate terminology aids in effective communication among medical teams and ensures appropriate coding for billing and treatment purposes.

In summary, while C83.93 specifically denotes non-follicular lymphoma affecting intra-abdominal lymph nodes, it is closely related to various other terms and classifications within the broader context of non-Hodgkin lymphoma.

The diagnosis of Non-follicular (diffuse) lymphoma, unspecified, intra-abdominal lymph nodes, classified under ICD-10 code C83.93, involves a comprehensive evaluation that includes clinical, laboratory, and imaging assessments. Below is a detailed overview of the criteria typically used for diagnosing this condition.

Clinical Presentation

Symptoms

Patients with diffuse lymphoma may present with a variety of symptoms, including:
- Lymphadenopathy: Swelling of lymph nodes, particularly in the abdomen.
- B Symptoms: These include fever, night sweats, and unexplained weight loss, which are common in lymphomas.
- Abdominal Pain or Discomfort: Due to enlarged lymph nodes or organ involvement.

Medical History

A thorough medical history is essential, including:
- Previous history of lymphoproliferative disorders.
- Family history of lymphoma or other cancers.
- Exposure to risk factors such as certain infections (e.g., Epstein-Barr virus) or environmental toxins.

Laboratory Tests

Blood Tests

• Complete Blood Count (CBC): To check for anemia, leukopenia, or thrombocytopenia, which may indicate bone marrow involvement.
• Lactate Dehydrogenase (LDH): Elevated levels can suggest aggressive disease and correlate with prognosis.

Biopsy

• Tissue Biopsy: A definitive diagnosis is often made through a biopsy of the affected lymph nodes or other involved tissues. Histopathological examination is crucial to differentiate between various types of lymphoma.

Immunophenotyping

• Flow Cytometry: This technique is used to analyze the surface markers on the cells obtained from the biopsy, helping to confirm the diagnosis of diffuse large B-cell lymphoma (DLBCL) or other non-follicular types.

Imaging Studies

Radiological Evaluation

• CT Scan or MRI: Imaging studies are essential for assessing the extent of the disease, particularly to visualize intra-abdominal lymph nodes and any organ involvement.
• PET Scan: Positron Emission Tomography can help in staging the lymphoma and assessing metabolic activity of the lymph nodes.

Staging and Classification

Ann Arbor Staging System

The Ann Arbor staging system is commonly used to classify the extent of lymphoma:
- Stage I: Involvement of a single lymph node region.
- Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm.
- Stage III: Involvement of lymph node regions on both sides of the diaphragm.
- Stage IV: Disseminated involvement of one or more extralymphatic organs.

Conclusion

The diagnosis of Non-follicular (diffuse) lymphoma, unspecified, intra-abdominal lymph nodes (ICD-10 code C83.93) requires a multifaceted approach that includes clinical evaluation, laboratory tests, imaging studies, and histopathological confirmation. Each of these components plays a critical role in establishing an accurate diagnosis and determining the appropriate treatment plan. If you have further questions or need more specific information, feel free to ask!

When addressing the standard treatment approaches for ICD-10 code C83.93, which refers to non-follicular (diffuse) lymphoma, unspecified, affecting intra-abdominal lymph nodes, it is essential to understand the nature of this condition and the typical therapeutic strategies employed.

Overview of Non-Follicular Lymphoma

Non-follicular lymphoma, particularly diffuse large B-cell lymphoma (DLBCL), is one of the most common types of non-Hodgkin lymphoma (NHL). It is characterized by the rapid proliferation of B-cells and can present in various anatomical locations, including the intra-abdominal lymph nodes. The treatment for this type of lymphoma is generally aggressive due to its fast-growing nature.

Standard Treatment Approaches

1. Chemotherapy

The cornerstone of treatment for diffuse large B-cell lymphoma typically involves chemotherapy. The most common regimen is R-CHOP, which includes:

• Rituximab: A monoclonal antibody targeting CD20 on B-cells.
• Cyclophosphamide: An alkylating agent.
• Doxorubicin (Adriamycin): An anthracycline antibiotic.
• Vincristine (Oncovin): A vinca alkaloid.
• Prednisone: A corticosteroid.

This combination is administered in cycles, usually every 21 days, and is designed to maximize the destruction of malignant cells while minimizing damage to normal tissues[1][2].

2. Radiation Therapy

In certain cases, especially when the lymphoma is localized, radiation therapy may be employed either as a primary treatment or as an adjunct to chemotherapy. This approach can help target residual disease in specific areas, such as intra-abdominal lymph nodes, after chemotherapy has been completed[3].

3. Stem Cell Transplantation

For patients who do not achieve a complete response to initial therapy or who experience a relapse, hematopoietic stem cell transplantation (HCT) may be considered. This procedure involves high-dose chemotherapy followed by the infusion of stem cells to restore bone marrow function. It is particularly relevant for younger patients or those with a good performance status[4].

4. Targeted Therapy and Clinical Trials

Emerging therapies, including targeted agents and immunotherapies, are increasingly being explored. For instance, CAR T-cell therapy has shown promise in treating relapsed or refractory DLBCL. Patients may also be eligible for clinical trials that investigate novel agents or combinations of therapies[5].

5. Supportive Care

Supportive care is crucial throughout the treatment process. This includes managing side effects of chemotherapy, such as nausea, fatigue, and risk of infection. Supportive measures may also involve transfusions, growth factors to stimulate blood cell production, and nutritional support[6].

Conclusion

The treatment of non-follicular lymphoma, particularly diffuse lymphoma affecting intra-abdominal lymph nodes, typically involves a combination of chemotherapy, radiation therapy, and potentially stem cell transplantation for more advanced cases. Ongoing research into targeted therapies and clinical trials continues to evolve the treatment landscape, offering hope for improved outcomes. Patients should work closely with their healthcare team to determine the most appropriate treatment plan based on their specific circumstances and overall health.

For further information or personalized treatment options, consulting with a hematologist or oncologist specializing in lymphomas is recommended.